Table 2.
Changes in marker gene expression in the placodal and non-neural ectoderm after injection of various constructs
| Injection | Control MO % (n) |
Eya1 MO1+21 % (n) |
Six1 MO1+21 % (n) |
Sox2MO+ Sox3MO1 % (n) |
Eya1 | Six1 | Eya1+Six1 |
Sox3 % (n) |
GR- Eya12 % (n, tb) |
GR- Six12 % (n, tb) |
GREya1+ GR-Six12 % (n, tb) |
GR- Sox32 % (n, tb) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phenotype | % (n, np) |
% (n, tb) |
% (n, np) |
% (n, tb) |
% (n, np) |
% (n, tb) |
|||||||||
| Eya1 | |||||||||||||||
| Reduced | 4 (45) |
54** (39) |
nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |
| Increased/ectopic | 0 (45) |
15* (39) |
nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd | nd |
| Six1 | |||||||||||||||
| Reduced | 8 (38) |
45** (81) |
nd | nd | 0 (62) |
0 (77) |
nd | nd | nd | nd | nd | nd | nd | nd | nd |
| Increased/ectopic | 0 (38) |
0 (81) |
nd | nd | 55 (62)3 |
44 (77)3 |
nd | nd | nd | nd | nd | nd | nd | nd | nd |
| Sox3 | |||||||||||||||
| Reduced | 12 (60) |
30* (156) |
62** (153) |
nd | 29 (52) |
53 (117) |
52 (46) |
59 (69) |
85 (40) |
90 (48) |
nd | 32 (34) |
70 (125) |
56 (135) |
nd |
| Increased/ectopic | 0 (60) |
12* (156) |
0 (153) |
nd | 29 (52) |
22 (117) |
4 (46) |
0 (69) |
35 (40) |
38 (48) |
nd | 32 (34) |
39 (137) |
63 (135) |
nd |
| Sox2 | |||||||||||||||
| Reduced | 6 (32) |
58** (51) |
54** (26) |
nd | 30 (63) |
50 (38) |
86 (28) |
71 (68) |
42 (26) |
36 (25) |
68 (34) |
35 (40) |
58 (106) |
46 (52) |
nd |
| Increased/ectopic | 0 (32) |
26* (31) |
0 (26) |
nd | 38 (63) |
37 (38) |
0 (28) |
6 (33) |
46 (26) |
59 (32) |
9 (34) |
68 (40) |
28 (114) |
69 (52) |
nd |
| N-Tubulin | |||||||||||||||
| Reduced | 9 (32) |
90** (206) |
66** (85) |
80** (40) |
60 (52) |
48 (42) |
88 (57) |
86 (14) |
79 (19) |
88 (17) |
91 (46) |
41 (41) |
41 (32) |
43 (82) |
42 (26) |
| Increased/ectopic | 0 (32) |
0 (206) |
0 (85) |
0 (40) |
4 (52) |
33 (42) |
0 (57) |
0 (14) |
11 (19) |
25 (20) |
0 (46) |
30 (41) |
22 (32) |
42 (82) |
0 (26) |
| NeuroD | |||||||||||||||
| Reduced | 24 (89) |
79** (238) |
70** (182) |
75** (60) |
64 (63) |
17 (201) |
83 (78) |
74 (87) |
72 (39) |
87 (37) |
81 (67) |
12 (42) |
62 (141) |
16 (195) |
49 (78) |
| Increased/ectopic | 0 (89) |
1 (146) |
0 (182) |
0 (60) |
3 (63) |
45 (201) |
0 (78) |
0 (87) |
5 (39) |
87 (37) |
0 (67) |
52 (42) |
29 (141) |
71 (195) |
0 (53) |
| Ngnr1 | |||||||||||||||
| Reduced | 10 (41) |
21 (116) |
45** (75) |
38* (37) |
44 (50) |
50 (117) |
75 (68) |
57 (62) |
76 (45) |
86 (21) |
45 (51) |
27 (33) |
57 (136) |
61 (79) |
67 (30) |
| Increased/ectopic | 0 (41) |
34** (116) |
36** (75) |
38** (37) |
14 (50) |
9 (117) |
4 (68) |
14 (52) |
4 (45) |
0 (21) |
18 (51) |
24 (33) |
5 (168) |
18 (79) |
0 (30) |
| Delta1 | |||||||||||||||
| Reduced | 7 (30) |
33* (75) |
58** (79) |
69** (36) |
49 (33) |
48 (58) |
68 (40) |
68 (66) |
93 (27) |
80 (25) |
52 (60) |
44 (27) |
72 (127) |
54 (41) |
64 (36) |
| Increased/ectopic | 0 (30) |
22* (75) |
18* (79) |
0 (36) |
27 (33) |
4 (58) |
48 (44) |
0 (66) |
0 (27) |
0 (25) |
32 (60) |
0 (27) |
2 (136) |
10 (41) |
0 (36) |
| p27Xic1 | |||||||||||||||
| Reduced | 17 (35) |
22 (72) |
29 (59) |
42* (33) |
43 (115) |
76 (72) |
75 (60) |
82 (71) |
80 (10) |
nd | 78 (55) |
35 (161) |
84 (83) |
39 (209) |
24 (46) |
| Increased/ectopic | 0 (35) |
51** (72) |
34** (59) |
49** (33) |
48 (115) |
20 (110) |
15 (40) |
0 (71) |
0 (10) |
nd | 38 (55) |
29 (161) |
8 (49) |
50 (209) |
17 (46) |
| CyclinA1 | |||||||||||||||
| Reduced | nd | nd | nd | nd | nd | 2 (46) |
0 (27) |
0 (38) |
nd | nd | nd | 0 (112) |
0 (37) |
0 (91) |
nd |
| Increased/ectopic | nd | nd | nd | nd | nd | 0 (46) |
0 (27) |
0 (38) |
nd | nd | nd | 0 (112) |
0 (37) |
1 (91) |
nd |
n: number of embryos analyzed at both neural plate (stage 14-16) and tail bud (stage 21-26) stage;
n, np: number of embryos analyzed at neural plate (stage 14-16) stage;
n, tb: number of embryos analyzed at tail bud (stage 21-26) stage;
nd: not determined;
1
Significant differences (X2 test; *: p< 0.05, **: p< 0.001) to control MO injections are indicated
2
Dexamethasone treatment from stages 16-18 on
3
Expression broader but weaker